Dashboard
Manage Tickers

ABBV AbbVie Inc.

NYSE abbvie.com


$ 217.73 $ -10.16 (-4.45 %)    

Friday, 31-Oct-2025 18:21:11 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.19 $ 3.02 (0.48 %)
DIA $ 475.66 $ 0.66 (0.14 %)
SPY $ 682.00 $ 2.23 (0.33 %)
TLT $ 90.18 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 218.04
$ 222.41
$ 217.75 x 100
$ 219.38 x 20
$ 216.00 - $ 223.87
$ 158.28 - $ 243.06
10,660,059
na
385.18B
$ 0.46
$ 102.36
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-17-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-18-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-02-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 02-19-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 11-06-2019 09-30-2019 10-Q
25 08-05-2019 06-30-2019 10-Q
26 05-03-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-07-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 02-16-2018 12-31-2017 10-K
32 11-07-2017 09-30-2017 10-Q
33 08-07-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 02-17-2017 12-31-2016 10-K
36 11-07-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-19-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

looking-into-abbvie-incs-recent-short-interest
Looking Into AbbVie Inc's Recent Short Int...
10/31/2025 20:00:42

nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday
Nasdaq 100 Rebounds, Amazon Jumps 10% On S...
10/31/2025 17:26:36

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-boost-dividend
AbbVie Raises 2025 Outlook Helped By Stron...
10/31/2025 15:47:20

AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfol...

abbvie-executive-says-administrations-focus-on-achieving-greater-reductions-in-2027-medicare-drug-price-negotiation-round-was-clear-but-outcomes-will-not-impact-long-term-outlook
AbbVie Executive Says Administration's Foc...
10/31/2025 13:58:14

-Reuters

abbvie-raises-fy2025-adj-eps-guidance-from-1038-1058-to-1061-1065-vs-1053-est
AbbVie Raises FY2025 Adj EPS Guidance from...
10/31/2025 11:57:41

AbbVie (NYSE:ABBV) raises FY2025 Adj EPS guidance from $10.38-$10.58 to $10.61-$10.65 vs $10.53 analyst estimate..

abbvie-q3-adj-eps-186-beats-179-estimate-sales-15776b-beat-15590b-estimate
AbbVie Q3 Adj. EPS $1.86 Beats $1.79 Estim...
10/31/2025 11:56:32

AbbVie (NYSE:ABBV) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.79 by 4.09 pe...

abbvie-increases-quarterly-dividend-from-164-per-share-to-173-per-share-payable-on-february-17-2026-to-shareholders-of-record-january-16
AbbVie Increases Quarterly Dividend From $...
10/31/2025 11:55:18

earnings-scheduled-for-october-31-2025
Earnings Scheduled For October 31, 2025
10/31/2025 11:11:48

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

abbvies-earnings-outlook
AbbVie's Earnings Outlook
10/30/2025 14:02:37

abbvie-says-canadas-drug-agency-recommends-elahere-be-reimbursed-with-conditions-for-treatment-of-certain-types-of-platinum-resistant-ovarian-cancers
AbbVie Says Canada's Drug Agency Recommend...
10/30/2025 11:31:44

ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC)ELAHERE® was submitted for reimbursement revie...

abbvie-says-in-two-replicate-phase-3-studies-rinvoq-achieved-co-primary-endpoints-of-50-reduction-in-total-vitiligo-area-scoring-index-from-baseline-and-75-in-facial-vitiligo-area-scoring-index
AbbVie Says In Two Replicate Phase 3 Studi...
10/29/2025 12:14:18

retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more
Retail Investors' Top Stocks With Earnings...
10/27/2025 14:38:22

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

live-on-cnbc-rob-sechan-announces-bought-more-abbvie
Live On CNBC, Rob Sechan Announces Bought ...
10/24/2025 16:30:49

qualcomm-aptiv-palo-alto-and-a-health-care-stock-on-cnbcs-final-trades
Qualcomm, Aptiv, Palo Alto And A Health Ca...
10/22/2025 12:17:16

Jason Snipe stays long on AbbVie (ABBV). Guggenheim analyst raises price target. QUALCOMM (QCOM) picked by Jim Lebenthal. Steph...

Core News & Articles
CNBC Halftime Report Final Trades: Palo Al...
10/21/2025 17:01:52

guggenheim-maintains-buy-on-abbvie-raises-price-target-to-242
Guggenheim Maintains Buy on AbbVie, Raises...
10/20/2025 12:34:56

Guggenheim analyst Vamil Divan maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $227 to $242.

abbvie-announced-topline-results-from-the-phase-3b4-head-to-head-select-switch-study-evaluating-the-efficacy-and-safety-of-upadacitinib-says-upadacitinib-outperforms-adalimumab-in-study-achieves-key-efficacy-endpoints-with-no-new-safety-risks
AbbVie Announced Topline Results From The ...
10/20/2025 12:10:56

Upadacitinib demonstrated superiority versus adalimumab for primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) ...

raymond-james-reiterates-outperform-on-abbvie-raises-price-target-to-250
Raymond James Reiterates Outperform on Abb...
10/17/2025 16:07:17

Raymond James analyst Gary Nachman reiterates AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $236 to ...

amazon-abbvie-datadog-and-a-financial-stock-cnbcs-final-trades
Amazon, AbbVie, Datadog And A Financial St...
10/14/2025 12:17:04

Analysts discuss stock performance and potential of AbbVie Inc, Amazon, Sixth Street Specialty Lending, and Datadog. Check out ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION